Format

Send to

Choose Destination
See comment in PubMed Commons below
Mt Sinai J Med. 1999 Mar;66(2):84-90.

DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus.

Author information

  • 1Loeb Health Research Institute, Ottawa Hospital, Canada.

Abstract

DNA vaccines, with which the antigen is synthesized in vivo after direct introduction of its encoding sequences, offer a unique method of immunization that may overcome many of the deficits of traditional antigen-based vaccines. By virtue of the sustained in vivo antigen synthesis and the comprised stimulatory CpG motifs, plasmid DNA vaccines appear to induce strong and long-lasting humoral (anti-bodies) and cell-mediated (T-help, other cytokine functions and cytotoxic T-cells) immune responses. In animal models, DNA vaccines against hepatitis B virus (HBV) give humoral and cell-mediated immunity superior to that of the current traditional antigen-based vaccines, indicating the possibility of a more effective prophylactic vaccine against HBV. Furthermore, DNA vaccines can overcome tolerance to and expression of HBV proteins in a transgenic mouse model of the HBV chronic carrier, opening up the possibility of an effective therapeutic DNA vaccine to treat chronic carriers of HBV.

PMID:
10100411
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk